01582nas a2200217   4500000000100000008004100001260001600042653001500058100001400073700001200087700001500099700001300114700001800127700001300145245014300158856015300301300000800454490000700462520088100469022001401350       2023                            d  bElsevier BV10atoxicology1 aDalhat MM1 aPotet J1 aMohammed A1 aChotun N1 aTesfahunei HA1 aHabib AG00aAvailability, accessibility and use of antivenom for snakebite envenomation in Africa with proposed strategies to overcome the limitations  uhttps://www.sciencedirect.com/science/article/pii/S2590171023000048/pdfft?md5=73c4b6916bc766084a02005011b8bf26&pid=1-s2.0-S2590171023000048-main.pdf  a1-70 v183 a<p>Africa remains one of the regions with the highest incident and burden of&nbsp;snakebite. The goal of the World Health Organization to halve the global burden of snakebite by 2030 can only be achieved if sub-optimal access to&nbsp;antivenoms&nbsp;in the most affected regions is addressed. We identified upstream, midstream, and downstream factors along the antivenom value chain that prevent access to antivenoms in the African region. We identified windows of opportunities that could be utilized to ensure availability, accessibility, and affordability for snakebite endemic populations in Africa. These include implementation of multicomponent strategies such as intensified advocacy, community engagement, healthcare worker trainings, and leveraging the institutional and governance structure provided by African governments to address the challenges identified.</p>
  a2590-1710